CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Duloxetine hydrochloride

Last Updated: February 8, 2008
Result type: Reports
Project Number: SR0125-000
Product Line: Reimbursement Review

Generic Name: Duloxetine hydrochloride

Brand Name: Cymbalta

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Depressive, Major Disorder (MDD)

Indications: Depressive, Major Disorder (MDD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 14, 2008

Recommendation Type: Do not list